CRISPR Therapeutics AG Aktie News

ZUG, Switzerland and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m.

Crispr Therapeutics AG commands a $5bn valuation, anchored by Casgevy's commercial approval and robust clinical data in SCD and TDT. Casgevy's slow commercial ramp is expected to accelerate in 2026, with revenue and patient growth as key valuation drivers. CRSP's pipeline—spanning in-vivo, CAR-T, and diabetes assets—offers major upside, but Casgevy remains the only revenue source.

CRISPR Therapeutics could perform well again next year, provided its clinical success continues. HCA Healthcare's prospects for next year remain uncertain, but its long-term outlook is strong.

CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company's stock, once a highflier, has declined from its peak.

CRISPR Therapeutics has figured out a way to successfully repair genetic code. Monetizing this know-how is the next step.

-Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 million cell dose, with the first systemic lupus erythematosus (SLE) patient achieving Definitions of Remission in SLE (DORIS) remission through Month 6-

CRISPR has incurred nearly $500 million in losses over the past four quarters. It's burning through cash as the result of its its gene-editing therapy's slow rollout.

A $1,000 investment can be an ideal amount to invest in an up-and-coming growth stock. The stocks below are still modest in size, with market capitalization of less than $6 billion.